Internal Medicine, Rheumatology · Nashville, TN
NPI
1952392797
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
222 22nd Ave N
Nashville, TN, 37203
Phone (629) 255-2183
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
135,325 services
Medicare patients, 2024
1,103
Average age 71
Drug cost, 2024
$4.6M
10,929 prescriptions
Company payments, 2025
$31K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Victor M Byrd was code J1602 (injection, golimumab, 1 mg, for intravenous use), 41,860 times for 60 patients. In total Victor M Byrd billed 135,325 services in 106 codes, and Medicare paid $1.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-06-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 41,860 | 60 | $8.88 | $372K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 32,000 | 15 | $3.33 | $107K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 6,700 | 13 | $33.25 | $223K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 4,870 | 34 | $0.10 | $486 |
| J0897 Injection, denosumab, 1 mg | Office | 2,580 | 29 | $20.44 | $53K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 2,470 | 12 | $25.04 | $62K |
| 99214 Office E&M - Established | Office | 930 | 529 | $76.24 | $71K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 867 | 34 | $0.22 | $195 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 563 | 391 | $11.18 | $6,293 |
| 77080 Standard X-ray | Office | 474 | 474 | $11.12 | $5,271 |
| 80053 Clinical Chemistry | Office | 301 | 203 | $10.20 | $3,071 |
| 36415 Venipuncture Blood Collection | Office | 293 | 230 | $8.46 | $2,479 |
| 85025 Blood Count | Office | 284 | 193 | $7.53 | $2,138 |
| 96413 Chemotherapy Administration | Office | 282 | 101 | $85.48 | $24K |
| 96365 Intravenous Infusion, Hydration | Office | 275 | 99 | $38.73 | $11K |
By year: 2022 $1.6M for 104,762 services; 2023 $1.5M for 121,070 services; 2024 $1.4M for 135,325 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 301 | 203 | $10.20 | $3,071 |
| 36415 Venipuncture Blood Collection | 293 | 230 | $8.46 | $2,479 |
| 85025 Blood Count | 284 | 193 | $7.53 | $2,138 |
| 86140 Clinical Chemistry | 221 | 176 | $5.00 | $1,106 |
| 85652 Clinical Chemistry | 170 | 131 | $2.65 | $451 |
| 86431 Immunoassay | 25 | 25 | $5.56 | $139 |
| 81001 Clinical Chemistry | 20 | 19 | $2.98 | $59.53 |
| 84550 Clinical Chemistry | 16 | 15 | $4.43 | $70.88 |
| 84443 Clinical Chemistry | 15 | 15 | $15.52 | $233 |
| 82550 Clinical Chemistry | 15 | 15 | $6.38 | $95.7 |
Medicare prescription drug claims, 2024
In 2024, the drug Victor M Byrd prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,358 prescriptions and refills. In total Victor M Byrd wrote 10,929 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,358 | 2,944 | 336 | $58K |
| Prednisone Generic | 1,335 | 2,418 | 372 | $12K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,038 | 1,038 | 139 | $28K |
| Gabapentin Generic | 794 | 1,104 | 167 | $14K |
| Methotrexate Methotrexate Sodium | 708 | 1,434 | 160 | $20K |
| Tizanidine Hcl Generic | 315 | 431 | 64 | $9,310 |
| Tramadol Hcl Generic | 296 | 298 | 43 | $2,338 |
| Meloxicam Generic | 277 | 559 | 82 | $1,907 |
| Duloxetine Hcl Generic | 240 | 516 | 53 | $5,147 |
| Pregabalin Generic | 234 | 284 | 44 | $5,386 |
| Leflunomide Generic | 233 | 456 | 61 | $18K |
| Celecoxib Generic | 220 | 445 | 58 | $6,837 |
| Allopurinol Generic | 202 | 463 | 45 | $2,564 |
| Zolpidem Tartrate Generic | 194 | 214 | 23 | $1,271 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 183 | 183 | 23 | $4,505 |
Brand drugs: - claims; generic drugs: 10,143 claims; opioid claims: 1,711.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Victor M Byrd $31K ($31K in general payments such as food, travel and fees) from 23 companies. The largest payer was Abbvie Inc. with $17K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 61 | $17K |
| Novartis Pharmaceuticals Corporation NVS | 38 | $6,045 |
| Amgen Inc. AMGN | 45 | $5,548 |
| UCB, Inc. UCB.BR | 23 | $475 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $300 |
| Janssen Biotech, Inc. JNJ | 11 | $275 |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $174 |
| GlaxoSmithKline, LLC. GSK | 7 | $169 |
| Pfizer Inc. PFE | 9 | $138 |
| Organon LLC OGN | 6 | $132 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.